Molecular and clinical disparity of EGFR-mutant non-small cell lung cancer (NSCLC) based on histopathological stage and EGFR molecular subtypes
{{output}}
Background: While epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are a cornerstone of therapy for advanced EGFR-mutant non-small cell lung cancer (NSCLC), resistance remains a major clinical challenge. ... ...
